Li Pang
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Tongji University (2018); United States Food and Drug Administration (2015–2025); Children's Hospital of Philadelphia (2005); University of Nottingham (2001–2019); Jilin University (2014); University of Utah (1992–1995); Montreal Heart Institute (2001–2006); Nottingham City Hospital (2000–2017); Hôpital Maisonneuve-Rosemont (2000); University of Pangasinan (2015); City Hospital (2001); First Hospital of Jilin University (2014); Centre Hospitalier de l’Université de Montréal (2001); First Bethune Hospital of Jilin University (2016); Nottingham Biomedical Research Centre (2018–2019); Food and Drug Administration (2025); Tongji Hospital (2018); The University of Texas Medical Branch at Galveston (2006); Université de Montréal (2000–2006)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Li Pang's research focuses on the application of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for evaluating drug-induced cardiotoxicity. This work involves developing and validating nonclinical regulatory studies that utilize human iPSC-CMs to predict potential cardiac safety issues associated with new drug candidates. Pang's publications detail methodologies for optimizing compound preparation and serum conditions for delayed repolarization evaluations using these iPSC-CMs.
Pang has also investigated the use of iPSC-CMs in proof-of-concept studies to predict cardiotoxicity from specific oncology drugs, such as doxorubicin. Beyond cardiotoxicity, the researcher's work extends to other areas of toxicology, including the assessment of mitochondrial function impairment in human hepatocytes by specific compounds, and the development of novel delivery systems for mRNA-based therapeutics, such as cationic polymeric micellar structures designed for enhanced intramuscular transfection.
With an h-index of 22 and over 2,500 citations across 84 publications, Pang is recognized as a highly cited researcher. Key collaborators at the National Center for Toxicological Research include William B. Mattes, Katy S Papineau, Lijun Ren, and Prathyusha Bagam. Pang leads a research group and has recently been active with publications in 2024 and 2025.
Metrics
- h-index: 22
- Publications: 84
- Citations: 2,582
Selected Publications
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
New Alternative Methods in Drug Safety Assessment (2023)
-
Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment (2022)
-
Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs (2022)
-
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools (2020)
-
Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations (2020)
-
Toxicity testing in the era of induced pluripotent stem cells: A perspective regarding the use of patient-specific induced pluripotent stem cell–derived cardiomyocytes for cardiac safety evaluation (2020)
-
Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers (2020)
-
Bridging the gap between data from human iPSC-derived cardiomyocytes and CiPA simulation (2019)
-
Sex differences in repolarization reserve, a possible mechanism for sex-related differences in drug-induced QT prolongation and torsades de pointes (2019)
-
Workshop Report (2019)
-
MS07.2 Sex Difference of Repolarization Reserve On Drug-induced QT Prolongation and Arrhythmias (2018)
-
Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs (2018)
Collaboration Network
Top Collaborators
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- New Alternative Methods in Drug Safety Assessment
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- New Alternative Methods in Drug Safety Assessment
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
- New Alternative Methods in Drug Safety Assessment
Similar Researchers
Based on overlapping research topics